HIV vaccine acceptability among high-risk drug users in Appalachia

A cross-sectional study

April M. Young, Ralph DiClemente, Daniel S. Halgin, Claire E. Sterk, Jennifer R. Havens

Research output: Contribution to journalArticle

Abstract

Background: A vaccine could substantially impact the HIV epidemic, but inadequate uptake is a serious concern. Unfortunately, people who use drugs, particularly those residing in rural communities, have been underrepresented in previous research on HIV vaccine acceptability. This study examined HIV vaccine acceptability among high-risk drug users in a rural community in the United States. Methods. Interviewer-administered questionnaires included questions about risk behavior and attitudes toward HIV vaccination from 433 HIV-negative drug users (76% with history of injection) enrolled in a cohort study in Central Appalachia. HIV vaccine acceptability was measured on a 4-point Likert scale. Generalized linear mixed models were used to determine correlates to self-report of being "very likely" to receive a 90% effective HIV vaccine (i.e. "maximum vaccine acceptability", or MVA). Adjusted odds ratios (AORs) and corresponding 95% confidence intervals (CIs) are reported. Results: Most (91%) reported that they would accept a preventive HIV vaccine, but concerns about cost, dosing, transportation constraints, vaccine-induced seropositivity, and confidentiality were expressed. Cash incentives, oral-administration, and peer/partner encouragement were anticipated facilitators of uptake. In multivariate analysis, men were significantly less likely to report MVA (AOR: 0.33, CI: 0.21 - 0.52). MVA was more common among participants who believed that they were susceptible to HIV (AOR: 2.31, CI: 1.28 - 4.07), that an HIV vaccine would benefit them (AOR: 2.80, CI: 1.70 - 4.64), and who had positive experiential attitudes toward HIV vaccination (AOR: 1.85, CI: 1.08 - 3.17). MVA was also more common among participants who believed that others would encourage them to get vaccinated and anticipated that their behavior would be influenced by others' encouragement (AOR: 1.81, 95% 1.09 - 3.01). Conclusions: To our knowledge, this study was among the first to explore and provide evidence for feasibility of HIV vaccination in a rural, high-risk population in the United States. This study provides preliminary evidence that gender-specific targeting in vaccine promotion may be necessary to promoting vaccine uptake in this setting, particularly among men. The data also underscore the importance of addressing perceived risks and benefits, social norms, and logistical constraints in efforts to achieve widespread vaccine coverage in this high-risk population.

Original languageEnglish (US)
Article number537
JournalBMC Public Health
Volume14
Issue number1
DOIs
StatePublished - May 30 2014

Fingerprint

Appalachian Region
AIDS Vaccines
Drug Users
Vaccines
Cross-Sectional Studies
Odds Ratio
HIV
Confidence Intervals
Vaccination
Rural Population
Confidentiality
Risk-Taking
Self Report
Population
Oral Administration
Motivation
Linear Models
Cohort Studies
Multivariate Analysis
Interviews

Keywords

  • AIDS vaccines
  • Attitude
  • Drug users
  • HIV
  • HIV vaccines
  • Psychological theory
  • Rural health
  • Vaccination

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

HIV vaccine acceptability among high-risk drug users in Appalachia : A cross-sectional study. / Young, April M.; DiClemente, Ralph; Halgin, Daniel S.; Sterk, Claire E.; Havens, Jennifer R.

In: BMC Public Health, Vol. 14, No. 1, 537, 30.05.2014.

Research output: Contribution to journalArticle

Young, April M. ; DiClemente, Ralph ; Halgin, Daniel S. ; Sterk, Claire E. ; Havens, Jennifer R. / HIV vaccine acceptability among high-risk drug users in Appalachia : A cross-sectional study. In: BMC Public Health. 2014 ; Vol. 14, No. 1.
@article{facecb9e3f704246883513190b6d4123,
title = "HIV vaccine acceptability among high-risk drug users in Appalachia: A cross-sectional study",
abstract = "Background: A vaccine could substantially impact the HIV epidemic, but inadequate uptake is a serious concern. Unfortunately, people who use drugs, particularly those residing in rural communities, have been underrepresented in previous research on HIV vaccine acceptability. This study examined HIV vaccine acceptability among high-risk drug users in a rural community in the United States. Methods. Interviewer-administered questionnaires included questions about risk behavior and attitudes toward HIV vaccination from 433 HIV-negative drug users (76{\%} with history of injection) enrolled in a cohort study in Central Appalachia. HIV vaccine acceptability was measured on a 4-point Likert scale. Generalized linear mixed models were used to determine correlates to self-report of being {"}very likely{"} to receive a 90{\%} effective HIV vaccine (i.e. {"}maximum vaccine acceptability{"}, or MVA). Adjusted odds ratios (AORs) and corresponding 95{\%} confidence intervals (CIs) are reported. Results: Most (91{\%}) reported that they would accept a preventive HIV vaccine, but concerns about cost, dosing, transportation constraints, vaccine-induced seropositivity, and confidentiality were expressed. Cash incentives, oral-administration, and peer/partner encouragement were anticipated facilitators of uptake. In multivariate analysis, men were significantly less likely to report MVA (AOR: 0.33, CI: 0.21 - 0.52). MVA was more common among participants who believed that they were susceptible to HIV (AOR: 2.31, CI: 1.28 - 4.07), that an HIV vaccine would benefit them (AOR: 2.80, CI: 1.70 - 4.64), and who had positive experiential attitudes toward HIV vaccination (AOR: 1.85, CI: 1.08 - 3.17). MVA was also more common among participants who believed that others would encourage them to get vaccinated and anticipated that their behavior would be influenced by others' encouragement (AOR: 1.81, 95{\%} 1.09 - 3.01). Conclusions: To our knowledge, this study was among the first to explore and provide evidence for feasibility of HIV vaccination in a rural, high-risk population in the United States. This study provides preliminary evidence that gender-specific targeting in vaccine promotion may be necessary to promoting vaccine uptake in this setting, particularly among men. The data also underscore the importance of addressing perceived risks and benefits, social norms, and logistical constraints in efforts to achieve widespread vaccine coverage in this high-risk population.",
keywords = "AIDS vaccines, Attitude, Drug users, HIV, HIV vaccines, Psychological theory, Rural health, Vaccination",
author = "Young, {April M.} and Ralph DiClemente and Halgin, {Daniel S.} and Sterk, {Claire E.} and Havens, {Jennifer R.}",
year = "2014",
month = "5",
day = "30",
doi = "10.1186/1471-2458-14-537",
language = "English (US)",
volume = "14",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - HIV vaccine acceptability among high-risk drug users in Appalachia

T2 - A cross-sectional study

AU - Young, April M.

AU - DiClemente, Ralph

AU - Halgin, Daniel S.

AU - Sterk, Claire E.

AU - Havens, Jennifer R.

PY - 2014/5/30

Y1 - 2014/5/30

N2 - Background: A vaccine could substantially impact the HIV epidemic, but inadequate uptake is a serious concern. Unfortunately, people who use drugs, particularly those residing in rural communities, have been underrepresented in previous research on HIV vaccine acceptability. This study examined HIV vaccine acceptability among high-risk drug users in a rural community in the United States. Methods. Interviewer-administered questionnaires included questions about risk behavior and attitudes toward HIV vaccination from 433 HIV-negative drug users (76% with history of injection) enrolled in a cohort study in Central Appalachia. HIV vaccine acceptability was measured on a 4-point Likert scale. Generalized linear mixed models were used to determine correlates to self-report of being "very likely" to receive a 90% effective HIV vaccine (i.e. "maximum vaccine acceptability", or MVA). Adjusted odds ratios (AORs) and corresponding 95% confidence intervals (CIs) are reported. Results: Most (91%) reported that they would accept a preventive HIV vaccine, but concerns about cost, dosing, transportation constraints, vaccine-induced seropositivity, and confidentiality were expressed. Cash incentives, oral-administration, and peer/partner encouragement were anticipated facilitators of uptake. In multivariate analysis, men were significantly less likely to report MVA (AOR: 0.33, CI: 0.21 - 0.52). MVA was more common among participants who believed that they were susceptible to HIV (AOR: 2.31, CI: 1.28 - 4.07), that an HIV vaccine would benefit them (AOR: 2.80, CI: 1.70 - 4.64), and who had positive experiential attitudes toward HIV vaccination (AOR: 1.85, CI: 1.08 - 3.17). MVA was also more common among participants who believed that others would encourage them to get vaccinated and anticipated that their behavior would be influenced by others' encouragement (AOR: 1.81, 95% 1.09 - 3.01). Conclusions: To our knowledge, this study was among the first to explore and provide evidence for feasibility of HIV vaccination in a rural, high-risk population in the United States. This study provides preliminary evidence that gender-specific targeting in vaccine promotion may be necessary to promoting vaccine uptake in this setting, particularly among men. The data also underscore the importance of addressing perceived risks and benefits, social norms, and logistical constraints in efforts to achieve widespread vaccine coverage in this high-risk population.

AB - Background: A vaccine could substantially impact the HIV epidemic, but inadequate uptake is a serious concern. Unfortunately, people who use drugs, particularly those residing in rural communities, have been underrepresented in previous research on HIV vaccine acceptability. This study examined HIV vaccine acceptability among high-risk drug users in a rural community in the United States. Methods. Interviewer-administered questionnaires included questions about risk behavior and attitudes toward HIV vaccination from 433 HIV-negative drug users (76% with history of injection) enrolled in a cohort study in Central Appalachia. HIV vaccine acceptability was measured on a 4-point Likert scale. Generalized linear mixed models were used to determine correlates to self-report of being "very likely" to receive a 90% effective HIV vaccine (i.e. "maximum vaccine acceptability", or MVA). Adjusted odds ratios (AORs) and corresponding 95% confidence intervals (CIs) are reported. Results: Most (91%) reported that they would accept a preventive HIV vaccine, but concerns about cost, dosing, transportation constraints, vaccine-induced seropositivity, and confidentiality were expressed. Cash incentives, oral-administration, and peer/partner encouragement were anticipated facilitators of uptake. In multivariate analysis, men were significantly less likely to report MVA (AOR: 0.33, CI: 0.21 - 0.52). MVA was more common among participants who believed that they were susceptible to HIV (AOR: 2.31, CI: 1.28 - 4.07), that an HIV vaccine would benefit them (AOR: 2.80, CI: 1.70 - 4.64), and who had positive experiential attitudes toward HIV vaccination (AOR: 1.85, CI: 1.08 - 3.17). MVA was also more common among participants who believed that others would encourage them to get vaccinated and anticipated that their behavior would be influenced by others' encouragement (AOR: 1.81, 95% 1.09 - 3.01). Conclusions: To our knowledge, this study was among the first to explore and provide evidence for feasibility of HIV vaccination in a rural, high-risk population in the United States. This study provides preliminary evidence that gender-specific targeting in vaccine promotion may be necessary to promoting vaccine uptake in this setting, particularly among men. The data also underscore the importance of addressing perceived risks and benefits, social norms, and logistical constraints in efforts to achieve widespread vaccine coverage in this high-risk population.

KW - AIDS vaccines

KW - Attitude

KW - Drug users

KW - HIV

KW - HIV vaccines

KW - Psychological theory

KW - Rural health

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84903514361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903514361&partnerID=8YFLogxK

U2 - 10.1186/1471-2458-14-537

DO - 10.1186/1471-2458-14-537

M3 - Article

VL - 14

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

IS - 1

M1 - 537

ER -